CI
Cigna Corporation
Medical - Healthcare Plans
Market Cap$74.35B
5Y Perf.+42.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CI vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
CVS
CVS Health Corporation
Medical - Healthcare Plans
Market Cap$111.32B
5Y Perf.+32.5%
CI vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CI | CVS |
|---|---|---|
| Industry | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $74.35B | $111.32B |
| Revenue (TTM) | $277.94B | $407.90B |
| Net Income (TTM) | $6.29B | $2.93B |
| Gross Margin | 9.3% | 13.9% |
| Operating Margin | 3.4% | 1.5% |
| Forward P/E | 9.3x | 12.1x |
| Total Debt | $31.46B | $93.59B |
| Cash & Equiv. | $7.68B | $8.51B |
CI vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CI
CVS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cigna Corporation (CI) | 100 | 142.9 | +42.9% |
| CVS Health Corporat… (CVS) | 100 | 132.5 | +32.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CI vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CI leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. CVS Health Corporation is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CI
Cigna Corporation
The Insurance Pick
CI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 11.3%, EPS growth 82.9%, 3Y rev CAGR 15.1%
- 135.9% 10Y total return vs CVS's 3.9%
- Lower volatility, beta 0.35, Low D/E 75.1%, current ratio 0.85x
Best for: growth exposure and long-term compounding
CVS
CVS Health Corporation
The Insurance Pick
CVS is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Beta 0.05 vs CI's 0.35
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CI | 11.3% revenue growth vs CVS's 7.8% |
| Value | CI | Lower P/E (9.3x vs 12.1x) |
| Quality / Margins | CI | Combined ratio 1.0 vs CVS's 1.0 (lower = better underwriting) |
| Stability / Safety | CVS | Beta 0.05 vs CI's 0.35 |
| Dividends | CI | 2.1% yield, 6-year raise streak, vs CVS's 3.1% |
| Momentum (1Y) | CVS | +35.2% vs CI's -13.7% |
| Efficiency (ROA) | CI | 4.1% ROA vs CVS's 1.1%, ROIC 10.4% vs 5.0% |
CI vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
CI vs CVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCILAGGINGCVS
CVSCVS Health Corporation
2leads
CICigna Corporation
2leads
6 Total Categories
CATEGORYLEADERvs CVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
CI5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CI9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CVS4/6
Risk & VolatilityBeta, volatility, and downside exposure
CVS2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
Evenly matched — CI and CVS each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS and CI operate at a comparable scale, with $407.9B and $277.9B in trailing revenue. Profitability is closely matched — net margins range from 2.3% (CI) to 0.7% (CVS).
| Metric | CICigna Corporation | CVSCVS Health Corpor… |
|---|---|---|
| RevenueTrailing 12 months | $277.9B | $407.9B |
| EBITDAEarnings before interest/tax | $12.1B | $9.4B |
| Net IncomeAfter-tax profit | $6.3B | $2.9B |
| Free Cash FlowCash after capex | $7.7B | $7.4B |
| Gross MarginGross profit ÷ Revenue | +9.3% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +3.4% | +1.5% |
| Net MarginNet income ÷ Revenue | +2.3% | +0.7% |
| FCF MarginFCF ÷ Revenue | +2.8% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.6% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +29.1% | +63.1% |
Evenly matched — CI and CVS each lead in 3 of 6 comparable metrics.
Valuation Metrics
CI leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 12.7x trailing earnings, CI trades at a 80% valuation discount to CVS's 62.5x P/E. On an enterprise value basis, CI's 8.3x EV/EBITDA is more attractive than CVS's 13.1x.
| Metric | CICigna Corporation | CVSCVS Health Corpor… |
|---|---|---|
| Market CapShares × price | $74.3B | $111.3B |
| Enterprise ValueMkt cap + debt − cash | $98.1B | $196.4B |
| Trailing P/EPrice ÷ TTM EPS | 12.72x | 62.49x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.30x | 12.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 8.34x | 13.10x |
| Price / SalesMarket cap ÷ Revenue | 0.27x | 0.28x |
| Price / BookPrice ÷ Book value/share | 1.79x | 1.46x |
| Price / FCFMarket cap ÷ FCF | 8.86x | 14.26x |
CI leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
CI leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $4 for CVS. CI carries lower financial leverage with a 0.75x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | CICigna Corporation | CVSCVS Health Corpor… |
|---|---|---|
| ROE (TTM)Return on equity | +15.1% | +3.9% |
| ROA (TTM)Return on assets | +4.1% | +1.1% |
| ROICReturn on invested capital | +10.4% | +5.0% |
| ROCEReturn on capital employed | +9.2% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.75x | 1.24x |
| Net DebtTotal debt minus cash | $23.8B | $85.1B |
| Cash & Equiv.Liquid assets | $7.7B | $8.5B |
| Total DebtShort + long-term debt | $31.5B | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | 6.77x | 4.19x |
CI leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CVS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CI five years ago would be worth $11,971 today (with dividends reinvested), compared to $11,843 for CVS. Over the past 12 months, CVS leads with a +35.2% total return vs CI's -13.7%. The 3-year compound annual growth rate (CAGR) favors CVS at 10.8% vs CI's 4.1% — a key indicator of consistent wealth creation.
| Metric | CICigna Corporation | CVSCVS Health Corpor… |
|---|---|---|
| YTD ReturnYear-to-date | +1.6% | +10.1% |
| 1-Year ReturnPast 12 months | -13.7% | +35.2% |
| 3-Year ReturnCumulative with dividends | +12.9% | +35.9% |
| 5-Year ReturnCumulative with dividends | +19.7% | +18.4% |
| 10-Year ReturnCumulative with dividends | +135.9% | +3.9% |
| CAGR (3Y)Annualised 3-year return | +4.1% | +10.8% |
CVS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than CI's 0.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.0% from its 52-week high vs CI's 83.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CICigna Corporation | CVSCVS Health Corpor… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.35x | 0.05x |
| 52-Week HighHighest price in past year | $338.89 | $88.63 |
| 52-Week LowLowest price in past year | $239.51 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +83.2% | +98.0% |
| RSI (14)Momentum oscillator 0–100 | 47.9 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 7.4M |
CVS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — CI and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates CI as "Buy" and CVS as "Buy". Consensus price targets imply 16.3% upside for CI (target: $328) vs 9.6% for CVS (target: $95). For income investors, CVS offers the higher dividend yield at 3.08% vs CI's 2.15%.
| Metric | CICigna Corporation | CVSCVS Health Corpor… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $328.00 | $95.20 |
| # AnalystsCovering analysts | 39 | 41 |
| Dividend YieldAnnual dividend ÷ price | +2.1% | +3.1% |
| Dividend StreakConsecutive years of raises | 6 | 0 |
| Dividend / ShareAnnual DPS | $6.06 | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.9% | 0.0% |
Evenly matched — CI and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway
CI leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). CVS leads in 2 (Total Returns, Risk & Volatility). 2 tied.
Best OverallCigna Corporation (CI)Leads 2 of 6 categories
Loading custom metrics...
CI vs CVS: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CI or CVS a better buy right now?
For growth investors, Cigna Corporation (CI) is the stronger pick with 11.
3% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Cigna Corporation (CI) offers the better valuation at 12. 7x trailing P/E (9. 3x forward), making it the more compelling value choice. Analysts rate Cigna Corporation (CI) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CI or CVS?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.
7x versus CVS Health Corporation at 62. 5x. On forward P/E, Cigna Corporation is actually cheaper at 9. 3x.
03Which is the better long-term investment — CI or CVS?
Over the past 5 years, Cigna Corporation (CI) delivered a total return of +19.
7%, compared to +18. 4% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: CI returned +135. 9% versus CVS's +3. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CI or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Cigna Corporation's 0. 35β — meaning CI is approximately 601% more volatile than CVS relative to the S&P 500. On balance sheet safety, Cigna Corporation (CI) carries a lower debt/equity ratio of 75% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CI or CVS?
By revenue growth (latest reported year), Cigna Corporation (CI) is pulling ahead at 11.
3% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CI or CVS?
Cigna Corporation (CI) is the more profitable company, earning 2.
2% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 2. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CI leads at 3. 3% versus 2. 6% for CVS. At the gross margin level — before operating expenses — CVS leads at 13. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CI or CVS more undervalued right now?
On forward earnings alone, Cigna Corporation (CI) trades at 9.
3x forward P/E versus 12. 1x for CVS Health Corporation — 2. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CI: 16. 3% to $328. 00.
08Which pays a better dividend — CI or CVS?
All stocks in this comparison pay dividends.
CVS Health Corporation (CVS) offers the highest yield at 3. 1%, versus 2. 1% for Cigna Corporation (CI).
09Is CI or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 9%, CI: +135. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CI and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CI is a mid-cap deep-value stock; CVS is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CI: 4.6% · CVS: 6.2%)P/E Ratio<
x
(CI: 12.7x · CVS: 62.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.